The global peptide receptor radionuclide therapy market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The increasing prevalence of neuroendocrine tumors is expected to impel the demand for peptide receptor radionuclide therapy (PRRT) as an increasing number of the patient pool. The establishment of reimbursement policies for Lutathera favors the […]